POLYMORPHISM AND TRANSPLANTATION BIOLOGY OF NOVEL HLA CLASS I GENES
新型HLA I类基因的多态性和移植生物学
基本信息
- 批准号:3810509
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:MHC class I antigen T lymphocyte alleles antibody formation bone marrow transplantation cell mediated lymphocytolysis test clone cells gene expression genetic polymorphism genetically modified animals graft versus host disease laboratory mouse major histocompatibility complex monoclonal antibody natural gene amplification polymerase chain reaction transfection
项目摘要
The overall objective of this proposal is to shed light on some of the
basic questions concerning the biology of the new class I proteins.
Because these genes were discovered after cloning and sequencing all of the
class I homologous sequences isolated from a human cell line, no antibodies
or sera specifically reactive with the protein products of these genes are
known. While expression can be detected at the mRNA level in various cells
and tissues, protein products have only been detected in HLA class I
deficient cell lines transfected with these genes. One characteristic of
the classical HLA-A,-B and -C antigens of importance to transplantation
biology is the striking polymorphism found at each locus. The first
specific aim of this proposal is to determine if, like the classical
antigens, the HLA-E, F(5.4) and G(6.0) antigens exhibit polymorphism. We
will use the polymerase chain reaction to specifically amplify E, F and G
cDNA and genomic sequences from a set of genetically diverse individuals
and determine their nucleotide sequence. If polymorphism is present at one
or more of these loci, we will use the same methods to correlate that
polymorphism with the outcome of an unrelated bone marrow transplant. The
second specific aim is to isolate monoclonal antibodies specifically
reactive with the HLA-E, -F(5.4) and G(6.0) molecules. We have constructed
a set of cell lines expressing these proteins and are planning construction
of additional lines. We will use these cells as a source of antigen for
the production of monoclonal antibodies. In order to optimize the
possibility of producing specific antibodies we are using transgenic mice
expressing human beta2 microglobulin and HLA-B27 for immunization. The
third specific aim is to determine if the HLA-E and G(6.0) gene products
are recognized by T cells. We will first attempt to generate T cell clones
reactive with transfectants of the class I deficient LCL .221 expressing
the HLA-E and G(6.0) proteins. If polymorphism exists, we will attempt to
demonstrate alloreactivity using a cell line from one individual expressing
an allo E or G(6.0) antigen using an in vitro CML test to generate T cell
clones reactive with the alloantigen. Learning the phenotype of these
clones as well as their reactivity with a panel of transfected cell lines
will be a fundamental step towards understanding the function of HLA-E and
G(6.0). In specific aim four we will investigate the potential of these
antigens to function as histocompatibility determinants. This work will
help to answer whether these antigens contribute to the problems
encountered in transplantation. This study will also provide important
information and reagents which will significantly add to our knowledge of
the expression and function of these new class I molecules.
本提案的总体目标是阐明一些
关于新I类蛋白质的生物学基本问题。
因为这些基因是在克隆和测序了所有
从人细胞系分离的I类同源序列,无抗体
或与这些基因的蛋白产物特异性反应的血清,
知道的 虽然可以在各种细胞中在mRNA水平上检测到表达,
和组织,蛋白质产物仅在HLA I类中检测到,
用这些基因转染的缺陷细胞系。 的一个特征
对移植重要的经典HLA-A、-B和-C抗原
生物学是在每个位点发现的惊人的多态性。 第一
这个建议的具体目的是确定,如果像经典的
抗原,HLA-E,F(5.4)和G(6.0)抗原表现出多态性。 我们
将使用聚合酶链反应特异性扩增E,F和G
来自一组遗传多样性个体的cDNA和基因组序列
并确定它们的核苷酸序列。 如果多态性存在于一个
或更多的这些位点,我们将使用相同的方法来关联,
多态性与无关骨髓移植的结果。 的
第二个具体目标是特异性分离单克隆抗体,
与HLA-E、-F(5.4)和G(6.0)分子反应。 我们已经构建
一组表达这些蛋白质的细胞系,
更多的线。 我们将用这些细胞作为抗原来源,
单克隆抗体的生产。 为了优化
我们使用转基因小鼠产生特异性抗体的可能性
表达人β 2微球蛋白和HLA-B27用于免疫。 的
第三个具体目标是确定HLA-E和G(6.0)基因产物是否
被T细胞识别。 我们将首先尝试产生T细胞克隆
与表达I类缺陷型LCL .221的转染子反应,
HLA-E和G(6.0)蛋白。 如果多态性存在,我们将尝试
使用来自一个个体的细胞系证明同种异体反应性,
使用体外CML测试产生T细胞的同种异体E或G(6.0)抗原
与同种异体抗原反应的克隆。 学习这些基因的表型
克隆以及它们与一组转染细胞系的反应性
将是理解HLA-E功能的基础性步骤,
G(6.0). 在第四个具体目标中,我们将研究这些目标的潜力。
抗原作为组织相容性决定簇发挥作用。 这项工作将
有助于回答这些抗原是否导致了这些问题
在移植过程中遇到的 这项研究还将提供重要的
信息和试剂,这将大大增加我们的知识
这些新的I类分子的表达和功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL GERAGHTY其他文献
DANIEL GERAGHTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL GERAGHTY', 18)}}的其他基金
NHP MHC ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT for transplantation studies
用于移植研究的 NHP MHC 等位基因发现和分型技术开发
- 批准号:
10018595 - 财政年份:2019
- 资助金额:
-- - 项目类别:
NHP MHC COMPLEX ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT - HIV/AIDS
NHP MHC 复杂等位基因发现和分型技术开发 - HIV/AIDS
- 批准号:
10018596 - 财政年份:2019
- 资助金额:
-- - 项目类别:
NHP MHC ALLELE DISCOVERY AND TYPING TECHNOLOGY DEVELOPMENT for transplantation studies
用于移植研究的 NHP MHC 等位基因发现和分型技术开发
- 批准号:
9364906 - 财政年份:2016
- 资助金额:
-- - 项目类别:
POLYMORPHISM AND TRANSPLANTATION BIOLOGY OF NOVEL HLA CLASS I GENES
新型HLA I类基因的多态性和移植生物学
- 批准号:
3791512 - 财政年份:
- 资助金额:
-- - 项目类别:
POLYMORPHISM AND TRANSPLANTATION BIOLOGY OF NOVEL HLA CLASS I GENES
新型HLA I类基因的多态性和移植生物学
- 批准号:
3803961 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Modulation of T lymphocyte Activation by Ã2-Adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
RGPIN-2019-06980 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10581488 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574979-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
A precision tumor neoantigen identification pipeline for cytotoxic T-lymphocyte-based cancer immunotherapies
用于基于细胞毒性 T 淋巴细胞的癌症免疫疗法的精准肿瘤新抗原识别流程
- 批准号:
10332251 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574984-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by ß2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574985-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
Modulation of T lymphocyte Activation by Ã2-adrenergic Receptor Signalling Pathways
α2-肾上腺素能受体信号通路对 T 淋巴细胞激活的调节
- 批准号:
574978-2022 - 财政年份:2022
- 资助金额:
-- - 项目类别:
University Undergraduate Student Research Awards
Investigating the cell-based activity of a new class of cytotoxic T-lymphocyte antigen-4 (CTLA-4) small molecule inhibitors
研究一类新型细胞毒性 T 淋巴细胞抗原 4 (CTLA-4) 小分子抑制剂的细胞活性
- 批准号:
444149 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Operating Grants
Novel pathways in T lymphocyte differentiation and function
T 淋巴细胞分化和功能的新途径
- 批准号:
RGPIN-2015-05491 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual
Modulation of T lymphocyte Activation by ß2-Adrenergic Receptor Signalling Pathways
通过 α2-肾上腺素能受体信号通路调节 T 淋巴细胞激活
- 批准号:
RGPIN-2019-06980 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Discovery Grants Program - Individual